{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:54:26Z","timestamp":1781711666649,"version":"3.54.5"},"reference-count":13,"publisher":"Norwegian Medical Association","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.24.0605","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T18:15:29Z","timestamp":1747073729000},"source":"Crossref","is-referenced-by-count":1,"title":["A man in his fifties with lymphoma, vomiting and diarrhoea"],"prefix":"10.4045","volume":"145","author":[{"given":"Jakob Lillemoen","family":"Drivenes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Lillemoen","family":"Drivenes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi Haukaas","family":"Bjerkreim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Pregun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor Jacob","family":"Eide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto Emil","family":"Nyquist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"ref=1","unstructured":"Chakari\u00a0W, Rangatchew\u00a0F, Toyserkani\u00a0NM et al. Necrobiotic xanthogranuloma misdiagnosed as a planocellular carcinoma. Ugeskr Laeger 2019; 181: V11180800. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30950371&dopt=Abstract"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Miguel\u00a0D, Lukacs\u00a0J, Illing\u00a0T et al. Treatment of necrobiotic xanthogranuloma - a systematic review. J Eur Acad Dermatol Venereol 2017; 31: 221\u201335. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27436448&dopt=Abstract","DOI":"10.1111\/jdv.13786"},{"key":"ref=3","unstructured":"Helsedirektoratet. Lymfekreft - handlingsprogram. https:\/\/www.helsedirektoratet.no\/retningslinjer\/lymfekreft-handlingsprogram Lest 28.10.2024."},{"key":"ref=4","unstructured":"Dioverti\u00a0MV, Razonable\u00a0RR. Cytomegalovirus. Microbiol Spectr 2016; 4: 4.4.20. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27726793&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1128%2Fmicrobiolspec.DMIH2-0022-2015"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Baniak\u00a0N, Kanthan\u00a0R. Cytomegalovirus Colitis: An Uncommon Mimicker of Common Colitides. Arch Pathol Lab Med 2016; 140: 854\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27472242&dopt=Abstract","DOI":"10.5858\/arpa.2015-0176-RS"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Griffiths\u00a0P, Reeves\u00a0M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol 2021; 19: 759\u201373. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34168328&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fs41579-021-00582-z","DOI":"10.1038\/s41579-021-00582-z"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Schneider\u00a0BJ, Naidoo\u00a0J, Santomasso\u00a0BD et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021; 39: 4073\u2013126. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34724392&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.21.01440","DOI":"10.1200\/JCO.21.01440"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Martinez Perez\u00a0P, Hanna\u00a0L, Jaynes\u00a0E et al. Infliximab rescue therapy in a case of severe granulomatous colitis associated with rituximab use. BMJ Case Rep 2024; 17: e257729. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38423571&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fbcr-2023-257729","DOI":"10.1136\/bcr-2023-257729"},{"key":"ref=9","unstructured":"Lipka\u00a0S, Katz\u00a0S, Crawford\u00a0JM. Fulminant Colitis Following Rituximab Therapy. Gastroenterol Hepatol (N Y) 2016; 12: 58\u201360. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27330506&dopt=Abstract"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"G\u00fcrcan\u00a0HM, Keskin\u00a0DB, Stern\u00a0JNH et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9: 10\u201325. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19000786&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.intimp.2008.10.004","DOI":"10.1016\/j.intimp.2008.10.004"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Mallepally\u00a0N, Abu-Sbeih\u00a0H, Ahmed\u00a0O et al. Clinical Features of Rituximab-associated Gastrointestinal Toxicities. Am J Clin Oncol 2019; 42: 539\u201345. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31136371&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FCOC.0000000000000553","DOI":"10.1097\/COC.0000000000000553"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Kristj\u00e1nsson\u00a0VB, Lund\u00a0SH, Gr\u00f6ndal\u00a0G et al. Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018. Scand J Gastroenterol 2021; 56: 46\u201352. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33280485&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1080%2F00365521.2020.1854847","DOI":"10.1080\/00365521.2020.1854847"},{"key":"ref=13","unstructured":"Folkehelseinstituttet. Legemiddelforbruket i Norge 2019-2023. https:\/\/www.fhi.no\/contentassets\/b0802ad9303347b682cf6a8fa701ec91\/legemiddelforbruket-i-norge-2019-2023-rapport-2024.pdf Lest 12.11.2024."}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["En mann i 50-\u00e5rene med lymfom, oppkast og diar\u00e9"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:24:04Z","timestamp":1781709844000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2025\/05\/noe-laere-av\/en-mann-i-50-arene-med-lymfom-oppkast-og-diare"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":13,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,5,13]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.24.0605","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]}}}